Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort

Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort

Abstract Introduction Using the ATN framework, we evaluated the potential of plasma biomarkers to identify abnormal brain amyloid-beta (Aβ) positron emission tomography (PET), tau-PET and neurodegeneration in a socioeconomically disadvantaged population-based cohort. Methods Community-dwelling demen...

Full description

Saved in:

Bibliographic Details
Main Authors:	Menayit Tamrat Dresse, Pamela C. L. Ferreira, Akshay Prasadan, Jihui L. Diaz, Xuemei Zeng, Bruna Bellaver, Guilherme Povala, Victor L. Villemagne, M. Ilyas Kamboh, Ann D. Cohen, Tharick A. Pascoal, Mary Ganguli, Beth E. Snitz, C. Elizabeth Shaaban, Thomas K. Karikari
Format:	Article
Language:	English
Published:	BMC 2025-07-01
Series:	Alzheimer’s Research & Therapy
Subjects:	Amyloid beta Tau pathology Neurodegeneration Neuroimaging ATN framework P-tau217
Online Access:	https://doi.org/10.1186/s13195-025-01803-w
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Identification of late-stage tau accumulation using plasma phospho-tau217Research in context
by: Marcel S. Woo, et al.
Published: (2024-11-01)

Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platformResearch in context
by: Azadeh Feizpour, et al.
Published: (2024-11-01)

A novel pThr217 tau monoclonal antibody reveals neuropathological heterogeneity in tauopathies
by: Giavanna Paterno, et al.
Published: (2025-06-01)

Plasma biomarkers for early detection of alzheimer’s disease: a cross-sectional study in a Japanese cohort
by: Masahito Kubota, et al.
Published: (2025-06-01)

Detecting amyloid and tau pathology in Parkinson’s disease, 4R-tauopathies and control subjects with plasma pTau217
by: Giulia Musso, et al.
Published: (2025-08-01)

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
by: Branislav Kovacech, et al.
Published: (2024-11-01)

Comparison of plasma p-tau217 and p-tau181 in predicting amyloid positivity and prognosis among Korean memory clinic patients
by: Hyuk Sung Kwon, et al.
Published: (2025-03-01)

Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology
by: David Wilson, et al.
Published: (2025-07-01)

Plasma phospho-tau217 as a predictive biomarker for Alzheimer’s disease in a large south American cohort
by: Neetesh Pandey, et al.
Published: (2025-01-01)

Associations of Plasma and CSF Osteocalcin Levels With CSF ATN Biomarkers and Cognitive Functions in Alzheimer's Disease
by: Xian‐Le Bu, et al.
Published: (2025-07-01)

Predicting amyloid status in mild cognitive impairment: the role of semantic intrusions combined with plasma biomarkers
by: Yao Lu, et al.
Published: (2025-06-01)

Clinical decision points for two plasma p‐tau217 laboratory developed tests in neuropathology confirmed samples
by: Anna E. Mammel, et al.
Published: (2025-01-01)

Early cerebrospinal fluid elevations of pTau-217 in severe traumatic brain injury subjects
by: Hamad Yadikar, et al.
Published: (2025-07-01)

Longitudinal trajectory of plasma p-tau217 in cognitively unimpaired subjects
by: Francisco Martínez-Dubarbie, et al.
Published: (2024-12-01)

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
by: Juan Lantero‐Rodriguez, et al.
Published: (2021-11-01)

Plasma phosphorylated tau 217 and amyloid‑β 42/40 for amyloid risk in subgroups
by: Heekyoung Kang, et al.
Published: (2025-08-01)

Optimizing timing and cost-effective use of plasma biomarkers in Alzheimer’s disease
by: Hsin-I Chang, et al.
Published: (2025-08-01)

Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform
by: Francisco Martínez-Dubarbie, et al.
Published: (2025-03-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-05-01)

Differential roles of human tau isoforms in the modulation of inflammation and development of neuropathology
by: Brian Spencer, et al.
Published: (2025-07-01)

Tau Imaging: Use and Implementation in New Diagnostic and Therapeutic Paradigms for Alzheimer’s Disease
by: Alexandra Gogola, et al.
Published: (2025-02-01)

The two cut‐offs approach for plasma p‐tau217 in detecting Alzheimer's disease in subjective cognitive decline and mild cognitive impairment
by: Giulia Giacomucci, et al.
Published: (2025-04-01)

C. DARYLL FORDE. Habitat. Economía y Sociedad
by: Margarita Nolasco
Published: (2010-05-01)

Retinal tau phosphorylation in Alzheimer's disease: A mass spectrometry study
by: Jessica Santiago, et al.
Published: (2025-10-01)

Temperature-Dependent Aggregation of Tau Protein Is Attenuated by Native PLGA Nanoparticles Under in vitro Conditions
by: Paul PS, et al.
Published: (2025-02-01)

Extracellular tau clearance is governed by its aggregation state and independent of microglial activation by LPS and IFN-γ
by: Andrew Shultz, et al.
Published: (2025-10-01)

Relationship between tau-PET and quantitative susceptibility mapping in atypical Alzheimer’s disease
by: Neha Singh-Reilly, et al.
Published: (2025-07-01)

Interplay Between Aging and Tau Pathology in Alzheimer’s Disease: Mechanisms and Translational Perspectives
by: Mohammed Alrouji, et al.
Published: (2025-06-01)

Exploring Tau-C, Tau-A, and C1M as biomarkers for Parkinson’s disease
by: Meryem Benmarce, et al.
Published: (2025-04-01)

Molecular Insights into Tau Pathology and its Therapeutic Strategies in Alzheimer's Disease
by: Futao Zhou, et al.
Published: (2024-10-01)

Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure A<sup>+</sup>T<sup>+</sup> (A<sup>+</sup>T<sub>1</sub><sup>+</sup>) Alzheimer’s Disease
by: Ioanna Tsantzali, et al.
Published: (2024-12-01)

Comparison of cerebrospinal fluid biomarkers in patients with severe COVID-19 neurological outcomes and Alzheimer’s disease
by: Fernanda G.Q. Barros-Aragão, et al.
Published: (2025-07-01)

Exploring the association between mild behavioral impairment and plasma p‐tau217: Implications for early detection of Alzheimer's disease
by: Maryam Ghahremani, et al.
Published: (2025-04-01)

Search for lepton-flavor-violating tau decays to ℓα at Belle
by: The BELLE collaboration, et al.
Published: (2025-08-01)

Natural bioactive compounds form herbal medicine in Alzheimer’s disease: from the perspective of GSK-3β
by: Mei Wang, et al.
Published: (2025-02-01)

Traditional Chinese medicine in Alzheimer's disease: From the perspective of GSK-3β and Tau hyperphosphorylation
by: Mei Wang, et al.
Published: (2024-12-01)

Effect of PHF-1 hyperphosphorylation on the seeding activity of C-terminal Tau fragments
by: Léa El Hajjar, et al.
Published: (2025-03-01)

Molecular mechanism of anti-luteolysis during the maternal recognition of pregnancy in cows
by: Aydın Güzeloğlu

Rivastigmine interferes with the pharmacological activity of hydromethylthionine on presynaptic proteins in the line 66 model of frontotemporal dementia
by: Karima Schwab, et al.
Published: (2025-01-01)

A Novel Microencapsulated Bovine Recombinant Interferon Tau Formulation for Luteolysis Modulation in Cattle
by: Emilio Lamazares, et al.
Published: (2025-07-01)